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Monoclonal antibodies (MAb) 1 have proven to be of great value in identifying the 
cellular lineages and  subsets  that  give rise  to  the  diversity of the  immune  system. 
Recently, interest has focused on the use of such antibodies to evaluate macrophage 
heterogeneity  (1-5),  and  these reagents  have  added measurably to  the  information 
attained using heterospecific antisera (6). The first and perhaps best characterized of 
these  antibodies, the  rat  anti-mouse  M1/70  (anti-Mac-i)  MAb,  defines an  antigen 
containing two  polypeptides of 170,000  and  95,000  mol wt  found  on  the surface of 
mouse macrophages, polymorphonuclear leukocytes (PMNL), and natural killer cells 
(1,  2,  7).  The  M1/70  MAb  cross-reacts  with  human  cells.  Mac-1  has  the  same 
distribution in humans as in the mouse (8). To date, no function has been attributed 
to this antigen. The  difficulty in ascribing function  to antibody-defined cell surface 
structures has been a  characteristic of studies on differentiation and cell type-specific 
antigens. 
Current  evidence indicates that cells of the myeloid lineage (mononuclear phago- 
cytes and  PMNL)  bear two distinct cell surface receptors for fragments of activated 
C3  (9-12,  and  reviewed  in  13).  The  type one  complement  receptor  (CR1)  displays 
specificity for C3b and C4b  (14-17).  This receptor has been  isolated and consists of 
a  single polypeptide chain  of 205,000  tool wt  (14,  15).  The  type three complement 
receptor  (CR3)  interacts  with  C3b  inactivator  cleaved  C3b  (C3bi)  and  further 
degradation products of C3bi termed a2D or C3d,g (16-22). To date, no information 
is  available concerning  the  structure  of CR3.  The  type  two  complement  receptor 
(CRz), which interacts with C3d,  is carried on lymphocytes but not on mononuclear 
phagocytes or PMNL  (13, 23). 
The  purpose  of  this  report  is  to  present  evidence  that  the  anti-Mac-1  MAb 
selectively blocks the  rosetting of C3bi-coated  erythrocytes to  murine  macrophages 
and  human  PMNL.  These  results  suggest  that  the  Mac-1  antigen  is  intimately 
associated with  or actually represents the  type three complement  receptor on  these 
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cells. This is one of the first cases in which a  MAb-defined differentiation antigen has 
been associated with a specific cell surface function. 
Materials and Methods 
Murine Macrophages.  Peritoneal exudate cells (PEC) were elicited from C3H/St mice (breed- 
ing colony of the Research Institute of Scripps Clinic, La Jolla, CA) or A/St mice (West Seneca 
Laboratories, Buffalo,  NY) by injection of 1.5 ml of protease peptone 3 d before cell harvest. 
PEC were harvested with Hanks' balanced salt solution (HBSS) with  10 mM Hepes and  1% 
fetal calf serum (FCS), and macrophages were isolated by adherence (2 h, 37°C) of 2 ×  105 
PEC per ml RPMI  1640 medium with 5 mM Hepes and 5% FCS in  16-mm Diam wells of 
culture  dishes  (3524;  Costar,  Data  Packaging,  Cambridge,  MA).  Nonadherent  cells  were 
removed by three washes with HBSS, 10 mM Hepes. 
Human PMNL.  PMNL were isolated from human blood using the method of English and 
Anderson (24). Preparations exhibited >99% viability and contained >95% PMNL, as assessed 
by the Wright-Giemsa stain. 
Purified human PMNL (2 X 105) in 1 ml HBSS were bound to 16-mm Diam flat-bottomed 
wells  in multiwell tissue culture plates  (Falcon Labware,  Div. of Beeton, Dickinson & Co., 
Oxnard, CA)  that previously had been treated with 300/zl of poly-L-lysine (PLL)  (70/~g/ml, 
Mr, >70,000; Vega Biochemicals, Tucson, AZ) as described (25). After the cells had adhered 
for  1 h at 37°C, the plates were washed and excess PLL blocked by addition of 0.5 ml HBSS 
containing 5  mg/ml  ovalbumin. Before  use,  the  adherent  cells  were  washed  with  HBSS 
containing 1 mg/ml ovalbumin and 200/~g/ml soy bean trypsin inhibitor. 
Preparation of Sheep Erythrocytes Bearing Antibody and Mouse Complement.  Sheep erythrocytes (E) 
obtained from the Colorado Serum Company, Denver, CO, were washed three times in saline 
solution, resuspended to  2%  (vol/vol) in HBSS  with  5  mM  Hepes  and no FCS  and then 
incubated with an equal volume of rabbit anti-sheep E  antibodies for 30 min at 37°C. IgG 
antibodies and IgM  antibodies (Cordis Laboratories, Miami, FL)  were  used at the highest 
dilution that had been shown to consistently give optimal rosetting (1:200  for IgG,  1:50 for 
IgM). After washing three times, the E-IgG and an aliquot of the E-IgM were set aside; the 
remainder of the E-IgM (2% in HBSS) was mixed with an equal volume of a 20% solution of 
freshly prepared A/St serum and incubated for 30 min at 37°C to produce complement (C)- 
coated E (E-IgM-C). These were also washed three times before use. 
Preparation of Bovine E Bearing Human C3 Fragments.  Bovine E were isolated from bovine blood 
preserved in Alsever's solution (Colorado Serum Company) and standardized to 109 cells/ml in 
gelatin-containing veronal-buffered saline (GVB).  E  bearing only C3b,  C3bi, or C3d  were 
prepared with purified human C components (26), as described elsewhere (17). Initial deposition 
of C3b onto the cells was accomplished by suspending 2 X  109 E in 200/d C3 (3 mg/ml) and 
activating with 15/~g trypsin for 5 min at 23°C. Cells were washed two times with GVB, and 
a cell-bound C3 convertase formed by incubation of the cells for 3 min at 37°C with 200/zl of 
a mixture of factor B (120/Lg/ml) and factor D  (2.6/~g/ml) and 1.2 mM magnesium sulfate. 
Surface-directed C3 deposition was then started by addition of 10/zl 0.2 M EDTA, pH 7.2, and 
50/~1 C3 (3 mg/ml), and was allowed to proceed for  15 min at 37°C. Cells were washed and 
subjected to two more cycles  of surface enzyme formation and C3b deposition. EC3b were 
finally washed in GVB and adjusted to 109 cells/ml. The number of C3b molecules bound per 
cell was determined either by using radiolabeled C3 during the cell preparation or by assessing 
the fl 1H globulin-binding  capacity of the cells, which has been shown to be proportional to the 
number of cell-bound C3b. EC3b were converted to EC3bi by incubation with fl 1H (40 #g/ml) 
and C3b inactivator (8/zg/ml) for 30 min at 37°C. At the end of the reaction, cells were washed 
and readjusted to 10g/ml. EC3d were produced from EC3bi by incubation of the latter with 10 
/zg/ml trypsin for  15 min at 37°C. The functional state of cell-associated C3 fragments was 
characterized as described  (25).  Briefly,  cell-bound C3b was capable of producing positive 
immune adherence reactivity with human erythrocytes, of forming the alternative pathway 
C3/C5  convertase with  factors  B  and  D  and magnesium ions, and of binding fllH. Cells 
bearing C3bi  were  lacking  these  three  functions but  exhibited  the  unique ability to  be 
agglutinated by purified bovine conglutinin  in the presence of calcium ions. Cells bearing C3d 
lacked all the above functions but retained 10% of the radioactivity previously associated with 1002  ANTI-Mac-1  SELECTIVELY  INHIBITS THE  C3bi  RECEPTORS 
C3b. A minimum of 100 C3b molecules or 500 C3bi molecules could be detected per cell by the 
functional tests. 
Rosette Analysis.  Adherent murine macrophages were washed with serum-free HBSS before 
use. Adherent human  PMNL were washed with HBSS containing  1 mg/ml ovalbumin and 
200/zg/ml soy bean trypsin inhibitor before use. The antibodies to be evaluated for inhibition 
of rosetting (see below) were then  added  (at  10 #g/ml unless otherwise indicated) in a  final 
volume of 0.5 ml HBSS. After a  10-min preincubation at room temperature, 50/~1 of the 2% 
opsonized E suspension was then added and the culture trays centrifuged (2 min at 200 g) to 
initiate binding of E. Trays were left undisturbed at room temperature for an additional 30 
rain, after which the nonadhering E were removed by agitating the trays during five changes 
of medium.  Monolayers  were  fixed  in  1%  glutaraldehyde  in  saline,  and  the  percent  of 
macrophages with more than five E was determined by observation on an inverted microscope. 
Blocking Antibodies.  In  most  experiments, hybridoma culture supernatants  diluted to  the 
specified concentration were used as the source of MAb. Concentrations were determined by 
Mancini radial immunodiffusion against anti-Fab. The M1/70  rat anti-mouse Mac-1  MAb, 
72b kappa, 106/~g/ml (1), the purified M1/70 IgG, and the F(ab')2 fragment were prepared as 
previously described (8). The 11-4.1 anti-H-2K  k MAb (27), y2a, 55/~g/ml, was used as a control 
in  most  experiments. The  MAb used  in Table I  ranged  from  23-235  /~g/ml in  the culture 
supernatant and have been previously described: M 1/42 (28);  M 1/84, M1/89.18, and M 1/9.3 
(29);  M5/III, M7/21, M7/83  (30);  and M17/4. 2 
Results 
Selective Inhibition by Anti-Mac-1  of Murine Macrophage C Receptor Function.  Our goal 
in the present study was to evaluate the possible relationship of the Mac-1 antigen to 
a  structure on  the macrophage surface of known  physiologic function. We initiated 
our investigation by evaluating the effect of anti-Mac- 1 on the binding of E-IgG and 
E-IgM-C to the macrophage Fc and C3 receptors. After a  10-rain preincubation with 
anti-Mac-1, anti-H-2K, or medium alone, appropriately opsonized E were adhered to 
the macrophage monolayers. The data in Fig. 1 indicate that, while neither anti-Mac- 
1 nor anti-H-2K had an appreciable effect on E-IgG binding, anti-Mac-1 completely 
blocked E-IgM-C binding, whereas anti-H-2K was without effect. Complete inhibition 
of E-IgM-C rosettes by anti-Mac-1  was  seen  at  all concentrations of the sensitizing 
IgM  antibody.  In  contrast,  anti-Mac-1  had  little effect  on  E-IgG rosettes,  even  at 
suboptimum IgG concentrations, showing that the selective effect on E-IgM-C rosettes 
was not related to the avidity of macrophages for opsonized E. 
Anti-Mac-l-mediated  inhibition  of  E-IgM-C  binding  to  murine  macrophages 
ranged  from  71-100%  in  eight  experiments  conducted  independently  in  our  two 
separate laboratories. In these experiments, a  very limited effect, ranging from 2-24% 
inhibition, was  also seen  in  the  E-IgG binding protocol. To  distinguish a  weak but 
potentially specific  inhibition  of E-IgG binding  by  anti-Mac-1  from  a  nonspecific 
competition by the  Fc portion of anti-Mac-1  for the  Fc receptor, we compared  the 
inhibition of E-IgG and I-IgM-C binding after incubation with intact or F(ab')2 anti- 
Mac-1. The data shown in Fig. 2 reveal that  the weak inhibition of E-IgG mediated 
by  intact  anti-Mac-1  was  totally absent  in  the  F(ab')z  preparation.  However,  the 
cleavage of the Fc portion of the antibody had no effect on  its capacity to block E- 
IgM-C. Thus, anti-Mac-1 showed an absolute preference for blocking C  receptor- vs. 
Fc receptor-mediated binding. 
2 Sanchez-Madrid,  F., D.  Davignon,  E.  Martz,  and T.  A. Springer.  1982. Functional  screening  for 
antigens associated with mouse T  lymphocyte-mediated  killing yields antibodies  to Lyt-2,3 and LFA-I. 
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Ftc.  l.  Anti-Mac-1 blocks binding of E-IgM-C but not E-IgG. Peptone-elicited mouse peritoneal 
macrophages were exposed to anti-H-2K (O) or anti-Mac- 1 (I), both at  10 pg/ml, or medium alone 
(O)  for  10  rain  at  room  temperature.  E  opsonized  with  the  indicated  lgG  or  IgM  antibody 
concentrations were then added. After centrifugation of E on to the macrophages, binding continued 
for 30 min at  room temperature. Unbound E  were removed by washing, and macrophages with 
more than five E bound were scored as positive. 
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FIc.  2.  (Left) Effect of intact or F(ab')2 anti-Mac- 1 on binding of opsonized E. Macrophages were 
preincubated with antibodies and rosetted with opsonized E, as in Fig.  1. Different concentrations 
of intact  (1~, I)  or F(ab')2 (O, O) anti-Mac-I were compared with controls without antibodies (A,  • 
A) for blocking E-IgG (open symbols) or E-IgM-C (closed symbols). 
FIc.  3.  (Right)  Inhibition of EC3bi  but not  EC3b  rosettes by treatment of human PMNL with 
anti-Mac- 1. Adherent human PMNL were incubated as described in Materials and Methods for 30 
rain  at  37°C  with  designated doses of anti-Mac-l  or  buffer  in  a  total  volume of 300 /xl. After 
incubation,  100 #1 of EC3b  (0)  or EC3bi  (©)  (5  ×  107 cells/ml) were added and cell-cell contact 
initiated by centrifugation for 5 min at  100 g. Rosette formation was allowed to proceed for 30 rain 
at 37°C. Cells were washed and rosettes were fixed by treatment with  1% glutaraldehyde and then 
scored by microscopic analysis. 
We  next  evaluated  a  panel  of MAb  to  determine  whether  other  antibodies  could 
also block  rosetting  (Table  I).  All  antibodies  except  anti-LFA-1  were  known  to  bind 
to  macrophages,  and  anti-H-2  and  the  M1/84  anti-pan-leukocyte  antibodies  bound 1004  ANTI-Mac-I  SELECTIVELY  INHIBITS THE  C3bi RECEPTORS 
TABLE  I 
Only Anti-Mac- 1 Blocks E-IgM-C Rosetting* 
Blocking MAb 
Percent rosetting 
macrophages 
E-IgG  E-IgM-C 
--  93  96 
Anti-Mac-1 (M1/70, y2b)  72  12 
Anti-H-2 (M 1/42, y2a)  91  95 
Anti-H-2 (M7/21, y2b)  7l  97 
Anti-Ly5 (M1/89.18, y2b)  82  94 
Anti-Ly5 (M1/9.3, y2a)  89  98 
Anti-Lgp 100 (M7/83, y2b)  92  96 
Anti-pan-leukocyte (M 1/84, y2a)  93  94 
Anti-pan-leukocyte (M5/111, y2a)  86  97 
Anti-LFA-1 (M17/4, y2a)  95  87 
* After  adherence,  peptone-elicited  macrophages  were incubated  with  the 
designated antibodies  (5 gg in  0.5  ml)  for  10  min  at  room  temperature. 
Opsonized E (50 gl) were then added and centrifuged onto the macrophages. 
After a 30-min incubation at room temperature,  unbound  E were removed 
by several changes of medium and the macrophages fixed in l% glutaralde- 
hyde before quantitating  binding. Positive cells were those with more than 
five E. 
TABLE  II 
Anti-Mac-1 Inhibits Murine Macrophage EC3bi Rosettes* 
Control  Anti-Mac-i 
Opsonized  Percent  Percent 
Percent  erythrocytes  rosetting  rosetting  inhibition 
macrophages  macrophages 
E-IgM  3.8  5.1  0 
E-IgM-C  97.6  22.9  77 
EG3b  41.6  44.6  0 
EC3bi  45.8  12.8  72 
* Rosette analysis and rosette inhibition were performed as outlined in Table 
I, except E bearing either C3b or C3bi (86,000 C3b/E)  were also used. 
to a  similar number of sites per cell as anti-Mac-1  (3).  Of the nine antibodies tested, 
several showed slight inhibition of E-IgG binding. However, only anti-Mac-1 was able 
to inhibit E-IgM-C binding. 
Selective Inhibition of CRa-mediated  Rosetting by Anti-Mac-l.  The data presented  thus 
far  indicated  that  treatment  of murine  macrophages  with  anti-Mac-1  specifically 
abrogated  the formation of rosettes with C-coated particles.  E  sensitized with serum 
as  the  source  of C  bear  C3  mainly  in  the  form  of C3bi  and  C3d  (13).  Because 
macrophages bear receptors for C3bi  but  not C3d,  this suggested  that  CR3  (specific 
for  C3bi)  was  blocked  by  anti-Mac-1.  To  more  rigorously  test  which  receptor was 
blocked,  we  prepared  E  bearing  only  homogenous  fragments  of C3  (C3b,  C3bi,  or 
C3d)  by  using  highly  purified  proteins  of  the  human  alternative  pathway.  The 
number of C3 fragments bound per cell was ~ 75,000-100,000.  Table II indicates that 
E  bearing  only  human  C3b  or  C3bi  form  rosettes  with  murine  macrophages.  The 
percentage  of rosette-positive cells  (41.6  and  45.8%,  respectively)  was  significantly D.  I. BELLER, T.  A. SPRINGER, AND R.  D.  SCHREIBER  1005 
reduced from the percentage that rosetted with E-IgM-C (97.6%). This difference is 
presumably a reflection of the lower affinity that exists between human C3 fragments 
and murine C3 receptors. In other experiments (data not shown), rosetting could not 
be shown between murine macrophages and EC3d.  Pretreatment of the macrophage 
population  with  anti-Mac-I  caused  a  77%  reduction  of EAC  rosettes  and  a  72% 
decrease in  rosettes formed with Ec3bi;  no decrease was observed in C3b-mediated 
rosette reactions. 
Because anti-Mac-I  is cross-reactive, its ability to inhibit  human C  receptors was 
also tested.  Rosette inhibition  analysis was performed with purified human  PMNL 
and E  bearing homogeneous human C3  fragments. In the controls, 90% of PMNL 
formed  CRa-dependent  rosettes  with  EC3b,  whereas  66%  formed  CR3-mediated 
rosettes with EC3bi.  Fig. 3 shows that anti-Mac-1 inhibited CRa rosetting in a  dose- 
dependent fashion. Maximum inhibition approached 90%, and anti-Mac-1 at 0.8 ~g/ 
ml was sufficient to inhibit the rosette reaction by 50%. In contrast to this result, anti- 
Mac-1  was devoid of inhibitory activity toward CRl-dependent  rosettes.  Even at  3 
#g/ml of anti-Mac-l,  the percentage of cells forming rosettes with  EC3b  remained 
unchanged from the buffer control. 
Discussion 
The results of this study indicate that  anti-Mac-1  was unique  among a  panel of 
MAb known to bind to macrophages in being able to block E-IgM-C binding.  Using 
particles that carried defined and homogeneous fragments of C3 on their surface, we 
showed  further  that  anti-Mac-1  specifically  blocked  CR3-mediated  rosetting.  No 
measurable inhibition  of CR1-  or Fc receptor-dependent  rosetting could  be found, 
even at doses of anti-Mac-1 that were 5 to  10 times in excess of those that abrogated 
CR3  rosetting.  The  most  likely  interpretation  of these  findings  is  that  the  Mac-1 
antigen  is  the  CR3.  However,  the  possibility  exists  that  anti-Mac-1  recognizes  a 
distinct  structure  that  is  intimately  associated  with  CR3  or  that  promotes  CRa 
function. 
C3 is the key component in the classical and alternative C  pathways (reviewed in 
26). When C3 is activated by cleavage to C3b, an internal thiolester bond is labilized 
(31-33).  C3b  can  then  become covalently attached  to cell surfaces by acylation of 
surface component  hydroxyl  or amino  groups by the  thiolester.  C3b  is  short  lived 
under normal physiological conditions. It is rapidly cleaved to C3bi (inactive) by the 
concerted action of the serum components fl 1H and C3b inactivator and then further 
degraded  to a  form denoted  a2D  or C3d,g  (19-22).  a2D  is  converted  to C3d  at  a 
much slower rate by serum proteases such as plasmin.  Sensitization  of E  with IgM 
and CS-deficient serum under the conditions used here results in C3 essentially all in 
the C3bi form (13). 
Three types of cell surface C receptors (CR) with specificity for C3 fragments have 
been described  (12-17).  CR1 is specific for C3b and C4b.  CR2 binds to C3d and to 
the  C3d  portion  of C3bi,  but  not  to C3b  (13,  23).  CR3  binds  to C3bi  (16-18).  At 
present, it is not known whether CR3 shows specificity for C3bi or for its degradative 
products, C3d,g or a2D (19-22). CR2 is not expressed on macrophages or granuiocytes, 
which are the cells under study in this report. CR~ is restricted to B lymphocytes and 
is a glycoprotein of 72,000 Mr (23).  CR1 is a glycoprotein containing a single 205,000 
Mr polypeptide (14).  CR1 activity on erythrocytes, lymphocytes, monocvtes, macro- 1006  ANTI-Mac-1 SELECTIVELY INHIBITS THE C3bi RECEPTORS 
phages, and neutrophils appears to be mediated by a common structure, as shown by 
blockade with antibody to the purified 205,000 Mr receptor. 
CR3 was only recently  distinguished  from CR2 by the  discovery that  CR3 binds 
C3bi  but  not  C3d,  whereas CR2 binds both C3d  and C3bi  (13).  CR3 is present  on 
monocytes, macrophages, and PMNL (13) and on 6-10% of human blood lymphocytes 
(18,  34).  This is in good agreement with the distribution  of Mac-1.  Mac-1  is present 
on  monocytes/macrophages,  granulocytes,  and  on  ~10%  of  human  blood 
"lymphocytes." This  lymphocyte subset  shows  greatly  enriched  natural  killer  and 
antibody-dependent cellular cytotoxic (ADCC)  activity (8).  Further, cells mediating 
ADCC  have  been  reported  to  be  enriched  for  the  C3bi  receptor  (34).  Kidney 
glomerular epitheloid cells are reported to express both CR1 and CR3 (12).  However, 
we were unable to test whether anti-Mac-1  blocked the glomerular CR3 because, in 
our hands,  EC3b  but  not  EC3bi  bound  to kidney glomeruli  (unpublished  observa- 
tions).  Kidney  is  negative  for Mac-1  by absorption  (2)  and  by immunoperoxidase 
straining of thin sections.  3 
We are in the process of purifying sufficient Mac- 1 to evaluate whether C3bi and 
Mac-1  antigen  interact  directly.  If successful, these  experiments would  confirm the 
identity of Mac-1 and CRy. Mac-1 would then be one of the very few differentiation 
or cell-specific antigens identified by antibodies to which a specific function has been 
attributed.  Moreover, such a  finding would immediately shed light on the structure 
of CRa because we know that Mac-1 contains two noncovalently associated glycopro- 
rein subunits, an a  subunit of 170,000 Mr and a fl subunit of 95,000 Mr (35).  Because 
this is a  large molecule, it is to be expected that  not  all MAb to it would  block the 
complement-binding site. 
The finding that anti-Mac-1 blocks CRa-mediated rosetting is particularly intrigu- 
ing because antibodies to a structurally related antigen on lymphocytes, LFA-1, block 
cytolytic T  lymphocyte-mediated killing (30,  36). Anti-LFA-1  MAb block killing by 
binding  to cytolytic T  lymphocyte effectors and  inhibiting  their adhesion  to target 
cells (37).  LFA-1 contains noncovalently associated a  and fl subunits of 180,000  and 
95,000 Mr  (35).  The M1/70  and M7/14  monoclonal antibodies defining Mac-1  and 
LFA-1  do  not  cross-react;  and,  as  expected,  anti-LFA-1  had  no  effect  on  C3bi- 
mediated  rosetting  (Table  I).  However,  some  antigenic  determinants  are  shared 
between Mac-1  and LFA-1  (35,  38).  Tryptic peptide mapping has shown the LFA-1 
and Mac-1/3 subunits are highly homologous, whereas the c~ subunits are distinct and 
appear to be products of different genes (35,  38).  However, homology between the c~ 
subunits at the level of amino acid sequence has not been ruled out and appears likely 
by analogy to other protein  families that  have shared or homologous subunits.  The 
structural homology between Mac-1 and LFA-1 suggests that there might be similar- 
ities  among  the  molecular  mechanisms  underlying  recognition  of foreign  cells  by 
macrophages and T  lymphocytes. 
Summary 
Anti-Mac-1  (M1/70),  a  rat  monoclonal  antibody  that  reacts  with  mouse  and 
human  macrophages,  polymorphonuclear  leukocytes  (PMNL),  and  natural  killer 
cells, selectively inhibited  complement receptor-mediated rosetting by murine  mac- 
3 Flotte, T., T. A. Springer, and G. J. Thorbecke. 1982. Dendritic ceils and macrophage staining by 
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rophages  and  human  PMNL.  Preincubation  of macrophages  with  anti-Mac-1  in- 
hibited  formation  of rosettes  with  sheep  erythrocytes  bearing  IgM  antibody  and 
murine C3 fragments. No inhibition was observed when other monoclonal antibodies 
that react with macrophages (such as anti-Ly5, anti-H-2, or anti-pan-leukocyte) were 
tested  at  10-fold higher  concentrations.  Anti-Mac-1  did  not  affect  macrophage  Fc 
receptor-mediated rosetting. Erythrocytes bearing homogeneous human C3 fragments 
C3b  (EC3b)  or C3bi  (EC3bi)  were used to test  the specificity of the murine  macro- 
phage  and  human  PMNL  complement  receptor  inhibited  by anti-Mac-1.  In both 
cases, anti-Mac-1 inhibited CR3-mediated rosetting of EC3bi but not CRl-dependent 
rosetting of EC3b. The results show that  Mac-1  is either identical  to CRa or closely 
associated  with  CRa  function.  This  is  one of the  first  cases  in which  a  monoclonal 
antibody-defined  differentiation  antigen  has  been  associated  with  a  specific  cell 
surface function. 
We acknowledge the technical assistance of K. Ammerman, A. Cosgrove, M. A. Brothers, and 
L. J. Hicks. 
Received  for publication 5 May 1982. 
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